In summary, noninvasive urine tests utilizing β2M, PGA3 and MUC3, in conjunction with clinically defined categories of PSA, have the potential to significantly enhance the ability to discriminate between BPH and localized PCa in the clinical setting. This evidence concerns the gene KLK3 and benign prostatic hyperplasia.